Sai Parenterals Limited 's subsidiary Noumed Pharmaceuticals Pty Limited has secured an exclusive Over-The-Counter (OTC) medicine supply agreement with Australia’s leading pharmacy network. The contract is valued at Australian Dollars (AUD) 202 Million, equivalent to INR 1300 crores, based on an exchange rate of 1 AUD = INR 64.5. This long-term agreement is effective from July 1, 2026, and is expected to significantly bolster the subsidiary's revenue streams over the contract period.

The agreement spans an initial term of 7.5 years, with a provision for a further extension of 3 years upon mutual consent between the parties involved. The deal translates to approximately AUD 27 Million per annum and includes a provision to add 12 new products every year, steadily increasing the contract's value and scope. The order has been awarded by an international entity, and the nature of the transaction is classified as an exclusive supply agreement. The company confirmed that the promoters, promoter group, or group companies do not hold any interest in the entity awarding the contract.

Key Contract Details

Strategic Benefits

The renewed agreement delivers substantial, multi-layered value by locking in predictable, recurring revenues across the 7½-year horizon. It further cements Noumed's presence in the Australian OTC market and expands Sai Parenterals' international pharmaceutical business. The agreement enhances manufacturing scale and operating leverage while supporting the continuous launch of new OTC products under leading Australian pharmacy brands.

Sai Parenterals clarified that the transaction does not fall within related party transactions and is conducted at arm's length. The disclosure was made to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The requisite details were provided in accordance with the SEBI Master Circular dated January 30, 2026.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0H9F01037/32f7d35b8f3e4308.pdf

Sai Parenteral's Limited will conduct a virtual analyst and institutional investor meeting on July 2, 2026, to discuss its business performance and outlook. The session is scheduled to take place between 10:00 AM and 11:00 AM IST and will be hosted by Axis Capital. The company has confirmed that no unpublished price sensitive information (UPSI) will be shared during the discussion.

Meeting Details

The meeting follows the disclosure requirements under Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The event is categorized as a group meeting and will be conducted virtually.

Disclosure Constraints

The company explicitly stated that the discussions will be limited to publicly available information. Officials from Sai Parenteral's Limited will participate in the session. The schedule remains subject to change due to exigencies on the part of the host or the company. The intimation was signed by Anil Kumar Karusala, Chairman and Managing Director.